On June 21, Gf Sec research reports pointed out that Notaibio (688076.SH) has a first-mover advantage in forward-looking layout, and the company's platform advantages are obvious, and its performance has entered a period of redemption. By the end of 2023, the company had obtained the US DMF/VMF numbers for 12 active pharmaceutical ingredients, and obtained FDA First Adequate Letters for active pharmaceutical ingredients such as Simpegutide and Liraglutide. In the future, the company's performance is expected to accelerate with the increase in sales of terminal products. Subsequently, the core multi-peptide products of the company are expected to further increase with the listing of terminal customer products, opening up the company's long-term income growth space. Referring to comparable companies in the industry and taking into account the potential product release space in the future patent expiration and innovative drug cooperation of GLP-type active pharmaceutical ingredients, a 45 times PE valuation is given to the company in 2024, corresponding to a reasonable value of 80.49 yuan/share. Maintain a “buy” rating.
研报掘金丨广发证券：维持诺泰生物“买入”评级，平台优势明显业绩进入兑现期
Research reports unearthed | GF Securities: Maintain a “buy” rating for Notai Biotechnology, with obvious platform advantages and performance entering the redemption period.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.